[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,50,96,167,186,220,242,278,305,328,399,420,442,464,491,522,544,574,606,625,653,681,710,730,748],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":4,"leadSponsor":46,"locationsCount":49},"100170772","national-eye-institute-biorepository-for-retinal-diseases-100170772",false,"NCT01496625","National Eye Institute Biorepository for Retinal Diseases","NEI Intramural Biorepository for Retinal Diseases","* INCLUSION CRITERIA:\n\nParticipants will be eligible if they:\n\n* Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children.\n* Manifest diagnosed or undiagnosed retinal disease(s), or could serve as an unaffected control suitable for comparison to participants with various retinal diseases, particularly AMD and diabetic retinopathy (taking into account matching factors such as age and past ocular history).\n\nEXCLUSION CRITERIA:\n\nParticipants will not be eligible if they:\n\n* Are unable or unwilling to give informed consent that includes collection and study of at least one peripheral blood sample.\n* Are unable or unwilling to give informed consent that includes use of NIH medical records and clinical samples for research.\n* Have a systemic disease that compromises the ability to provide adequate ophthalmologic examination or treatment.",true,"ALL","2 Years","120 Years",{"count":21,"type":22},650,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time. They also want to study body tissues and blood to understand the nature of eye disease. Studying genes, cells, and tissues may help them understand why some people get eye problems and others do not, or why some people respond to treatment while others do not. Researchers want to collect physical samples and personal data to develop a National Eye Institute database.\n\nObjectives:\n\n\\- To collect health information and blood and tissue samples from people with and without eye diseases, to be used in research studies.\n\nEligibility:\n\n* Individuals at least 2 years of age with different types of eye disease.\n* Healthy volunteers with no history of eye disease.\n\nDesign:\n\n* Participants may be recruited from National Eye Institute studies or may be referred from other sources.\n* Participants will be screened with a physical exam and medical history. They will also have a full eye exam. Questions will be asked about family medical history, especially about eye disease.\n* Blood samples will be collected. Other samples, such as saliva, tears, hair, stool, and urine, may be collected as needed. Adult participants may also provide a skin sample.\n* Tissue or fluid from eye collected as part of eye care or treatment may also be added to the database.\n* No treatment will be provided as part of this study.",[26,27,28,29,30],"Age-Related Macular Degeneration","Diabetic Retinopathy","Von Hippel-Lindau Syndrome","Retinal Disease","Retinal Vein Occlusion",[32,29,27,33,34,35,36,37,38],"Biological Specimens","Phenotype-Genotype correlation","Age-Related Macular Degeneration (AMD)","Natural History","AMD","Healthy Volunteer","HV","RECRUITING","2026-06-27",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":43},"2012-06-18",{"name":47,"class":48},"National Eye Institute (NEI)","NIH",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":75,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100584599","phase-3-study-to-evaluate-sepofarsen-in-subjects-with-leber-congenital-amaurosis-lca-type-10-hyperion-100584599","NCT06891443","Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)","A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene","HYPERION","Inclusion Criteria:\n\n1. Confirmed clinical diagnosis of LCA10 and a molecular diagnosis of homozygosity or compound heterozygosity for the c.2991+1655A\\>G mutation in CEP290.\n2. Adults: \\>=18 years \u002F Minors: 6 to \\\u003C18 years.\n3. BCVA (FrACT) equal to or worse than logMAR +0.4 (approximate Snellen equivalent 20\u002F50) to +2.9 logMAR based on quantifiable, reliable FrACT. LP subjects with documented evidence of prior better vision eligible.\n4. Symmetrical disease between the two eyes as defined by a BCVA (FrACT) within 0.2 logMAR at baseline.\n5. Detectable ONL in the macular area as determined by the CRC at Screening.\n\nExclusion Criteria:\n\n1. Mutations in genes other than the CEP290 gene associated with other IRD diseases or syndromes.\n2. Presence of any ocular pathology in either eye that may make comparison of the eyes not feasible.\n3. Presence of unstable concurrent CME, or subject started on (or changed dose of) topical or systemic carbonic anhydrase inhibitor treatment in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment).\n4. Presence of any clinically significant lens opacities\u002Fcataracts based on the AREDS lens grading scale.\n5. Any prior receipt of genetic (RNA or DNA therapy) or stem-cell therapy for ocular or non-ocular disease, including sepofarsen.","6 Years",{"count":60,"type":22},32,"INTERVENTIONAL",[63],"PHASE3","The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\\>G (p.Cys998X) mutation in the CEP290.",[66,67,68,69,70,71,72,73,74,29],"Leber Congenital Amaurosis 10","Blindness","Leber Congenital Amaurosis","Sensation Disorders","Vision Disorder","Neurological Manifestations","Eye Diseases, Hereditary","Eye Diseases","Eye Disorders Congenital",[76,77,78,79,80,81,82,83,84],"LCA10","p.Cys998X","Antisense oligonucleotides","RNA therapy","QR-110","sepofarsen","CEP290","Leber's Congenital Amaurosis","c.2991+1655A>G","2026-06-24",{"date":87,"type":43},"2026-06-25",{"date":89,"type":43},"2025-06-04",{"date":91,"type":22},"2028-10",{"name":93,"class":94},"Laboratoires Thea","INDUSTRY",17,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":61,"phases":107,"briefSummary":109,"conditions":110,"keywords":126,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660","NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","18 Years",{"count":106,"type":22},500,[108],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[29,26,111,112,113,114,115,116,117,118,67,119,120,121,122,123,124,125],"Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[127,128,129,130,131,132,133,134,135,29,124,136,137,138,139,140,141,142,143,144,111,112,145,146,147,123,116,115,113,148,149,150,151,152,153,154,155,156,118,67,157,125],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss",{"date":159,"type":43},"2026-06-29",{"date":161,"type":43},"2016-01",{"date":163,"type":22},"2028-07-31",{"name":165,"class":94},"MD Stem Cells",4,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":19,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":4,"leadSponsor":185,"locationsCount":49},"100143971","genotype-phenotype-study-of-patients-with-plaquenil--induced-retinal-toxicity-with-evaluation-of-the-abca4-gene-100143971","NCT01145196","Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene","Genotype - Phenotype Study of Patients With Plaquenil-induced Retinal Toxicity","* INCLUSION CRITERIA:\n\n  1\\. Affected participants must be 18 years of age or older and have:\n* History of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or Sjogren's syndrome, and\n* History of Plaquenil(R) use, and\n* Evidence of Plaquenil(R)-induced retinal toxicity, based on clinical findings.\n\n  2\\. Unaffected volunteers must be 18 years of age or older and have:\n* History of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or Sjogren's syndrome, and\n* History of Plaquenil(R) use, and\n* No retinal disease upon examination within the last six months.\n\n  3\\. All participants must be able to:\n* Provide their own consent, and\n* Safely provide a blood sample.\n\n\\\u003CTAB\\>\n\nEXCLUSION CRITERIA:\n\nParticipants with other known (genetic) retinal disease including but not limited to: Stargardt's disease and cone or cone-rod dystrophy whose diagnosis preceded their Plaquenil(R) use. Participants with no known previous genetic diagnosis but with clinical findings associated with a genetic diagnosis, such as parafoveal or macular flecks which are associated with Stargardt's disease or fundus flavimaculatus, will also be excluded.",{"count":175,"type":22},320,"Background:\n\n\\- Plaquenil (hydroxychloroquine) is an anti-inflammatory drug that is used to treat some autoimmune diseases such as lupus and rheumatoid arthritis. This drug can damage the retina by causing a condition called Plaquenil-induced retinal toxicity, which may lead to vision loss. However, most people taking Plaquenil do not develop this problem. Researchers are interested in studying whether differences in a person's genes explain why some people develop Plaquenil-induced retinal toxicity while others do not.\n\nObjectives:\n\n\\- To investigate possible correlations between certain genes or genetic mutations and Plaquenil-induced retinal toxicity.\n\nEligibility:\n\n* Individuals at least 18 years of age who have previously used Plaquenil.\n* History of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or Sjogren's syndrome.\n* Both individuals who have and have not developed Plaquenil-induced retinal toxicity will be eligible for this study.\n\nDesign:\n\n* The study requires five annual outpatient visits to the NIH Clinical Center.\n* Participants will provide a personal and family medical history, and will have a full eye examination.\n* Participants will also provide blood samples for genetic analysis, including whole exome and whole genome sequencing.\n* No treatment will be provided as part of this protocol.",[178,29],"Genotype",[29,180,35],"Plaquenil-Induced","2026-06-23",{"date":85,"type":43},{"date":184,"type":43},"2010-08-23",{"name":47,"class":48},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":61,"phases":194,"briefSummary":195,"conditions":196,"keywords":203,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":219},"100551076","the-genetics-navigator-evaluating-a-digital-platform-for-genomics-health-services-100551076","NCT06455384","The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services","Inclusion:\n\n* Adult patients (18 years of age or older) who are referred to participating clinicians at Mount Sinai Hospital for clinical genetic testing.\n* Parents\u002Flegal guardians (18 years of age or older) of pediatric patients who are referred to participating clinicians at SickKids for clinical genetic testing.\n\nExclusion:\n\n* Known not to be eligible for clinical genetic testing in Ontario\n* Requires urgent clinical genetic testing or prenatal genetic testing\n* Not fluent in English (speaking and reading)",{"count":193,"type":22},170,[108],"Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.",[197,198,29,199,200,201,202],"Cardiac Conditions","Connective Tissue Diseases","Epilepsy in Children","Neurodevelopmental Disorders","Cancer","Polyposis",[204,205,206,207,208,209],"Genomic Sequencing","Randomized Controlled Trial","Clinical Utility","Personal Utility","Decision Aid","Incidental Findings","2026-06-19",{"date":85,"type":43},{"date":213,"type":43},"2025-10-28",{"date":215,"type":22},"2027-07",{"name":217,"class":218},"Unity Health Toronto","OTHER",3,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":16,"sex":17,"minAge":227,"maxAge":19,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":4,"leadSponsor":241,"locationsCount":49},"100165906","cell-collection-to-study-eye-diseases-100165906","NCT01432847","Cell Collection to Study Eye Diseases","Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls","* INCLUSION CRITERIA:\n\nTo be eligible, participants must meet the following inclusion criteria.\n\n1. Have the ability to understand and sign an informed consent or have a parent\u002Flegal guardian to do so if they are minor children or have a legally authorized representative if they are adults without consent capacity.\n2. Participant meets one of the following criteria:\n\n   1. Participant has been diagnosed with an ocular condition of interest including but not limited to: degenerative retinal diseases, optic atrophy, microphthalmia\u002Fanophthalmia, ciliopathy, and other ocular developmental or degenerative conditions.\n   2. Participant is free of eye diseases and could serve as an unaffected control. Participant's age, sex, and ethnicity must match an existing participant with one of the eye diseases under study. Control participants matched to AMD participants must not have drusen greater than 63 microns in size.\n3. Adult participant is able to provide a punch skin biopsy and 30 mL of peripheral venous blood OR child participant is able to provide a punch skin biopsy and the lesser of 5 mL\u002Fkg or 30 mL of peripheral venous blood. Healthy, unaffected children will only have one skin punch biopsy done 3mm or less in size. In affected participants, an additional punch may be gathered if the initial sample does not contain adequate cells. This will be taken from children ages seven years and older. Sampling of ten occipital hairs and\u002For saliva may be pursued at the investigator's discretion. Participants not able to provide a skin biopsy or blood sample may opt to provide 100-200 ml of fresh urine. As a rule, samples will be collected on non-sedated\u002Fanesthetized participants. Sedation\u002Fanesthesia will NOT be used solely for the purpose of sample collection. In rare instances where a minor requires sedation for another medically indicated procedure, samples may be collected at the time of sedation\u002Fanesthesia. Because young children may not be able to cooperate with sample collection, those unable to provide a skin biopsy, urine sample or a blood sample may be excluded from the study, based on the judgment of the examining investigator.\n4. Participant meets one of the following criteria:\n\n   1. Participant affected with an ocular condition is one year of age or older.\n   2. Participant affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n   3. Unaffected participant is seven years of age or older and willing and able to provide assent.\n\nEXCLUSION CRITERIA:\n\nA participant is not eligible if any of the following exclusion criteria are present.\n\n1. Participant is unable to comply with study procedures.\n2. Participant has a systemic disease that, in the opinion of the investigator, compromises the ability to provide adequate samples. Examples of co-existing diseases that would exclude a participant include a bleeding diathesis or a genetic susceptibility to infections, particularly cutaneous infections.\n\nADDITIONAL CRITERIA FOR CLNICAL-GRADE CELL LINE GENERATION:\n\nThe additional eligibility criteria must be met for participants donating samples for the generation of clinical-grade cell lines.\n\nInclusion Criteria\n\n1. Participant must be greater than 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment.\n2. Participant is able to provide a punch skin biopsy and 200 ml of peripheral venous blood.\n3. Participant is willing and eligible to co-enroll in NEI protocol 15-EI-0128.\n\nExclusion Criteria\n\n1. Participant has medical history that includes any of the following:\n\n   1. Thrombocytopenia or other blood dyscrasias\n   2. Bleeding diathesis\n   3. Antibiotic use within the prior 48 hours\n   4. Active cancer or history of cancer within the past five years\n   5. History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood\n\n      Banking and Transfusion Services, American Association of Blood Banks.\n   6. Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov\u002Ftravel)\n   7. At risk for the possible transmission of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, \"Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creuzefeldt-Jackob Disease (CJD) and Variant Creuzefeldt-Jackob Disease (vCJD) by Blood and Blood Products\"\n2. Participant is currently febrile (temperature \\> 38 degrees C)\n3. Participant has Hemoglobin level:\n\n   * African American women \\\u003C11.5 grams\u002FdL\n   * Other women \\\u003C 12.0 grams\u002FdL\n   * Men \\\u003C12.5 grams\u002FdL\n4. Participant has low hematocrit (HCT):\n\n   * African American women \\\u003C 34%\n   * Other women \\\u003C36%\n   * Men \\\u003C38%\n5. Participant has Platelets \\\u003C150 x 103\u002FmicroL\n6. Participant has Absolute neutrophil count \\\u003C1.0 x 103\u002FmicroL.\n7. Participant has positive tests for blood borne pathogens (as required by the Standards for Blood Banks and Transfusion Services, American Association of Blood Banks. The currently required tests include anti-HIV1\u002F2, anti-HCV, anti-HBc, Anti-HTLV I\u002FII, anti-T. Cruzi, HBsAg, syphilis, and molecular testing for West Nile virus, HCV, HBV, and HIV-1).","1 Day",{"count":229,"type":22},930,"Background:\n\n\\- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases. However, cells collected from hair follicles, skin, saliva, urine, and blood can be used for research. Researchers want to collect cells from people with Best disease, L-ORD, and AMD, and compare their cells with those of healthy volunteers.\n\nObjectives:\n\n\\- To collect hair, skin, saliva, urine, and\u002For blood samples to study three eye diseases that affect the retina: Best disease, L-ORD, and AMD.\n\nEligibility:\n\n* Individuals affected with ocular condition is one year of age or older.\n* Individuals affected with Best disease, L-ORD, or AMD is 18 years of age or older.\n* Unaffected individuals are seven years of age or older.\n\nDesign:\n\n* The study requires one visit to the National Eye Institute.\n* Participants will be screened with a medical and eye disease history. They may also have an eye exam.\n* Participants will provide a hair sample, saliva sample, urine sample, blood sample, and\u002For a skin biopsy. The hair will be collected from the back of the head, and the skin will be collected from the inside of the upper arm.",[29,36,232,111],"Retinal Degeneration",[234,235,34,35,232,26,36],"Best Disease","Late-Onset Retinal Degeneration (L-ORD)","2026-06-18",{"date":238,"type":43},"2026-06-22",{"date":240,"type":43},"2011-09-07",{"name":47,"class":48},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":61,"phases":253,"briefSummary":255,"conditions":256,"keywords":261,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":277},"100564284","phase-2-study-to-evaluate-ultevursen-in-subjects-with-retinitis-pigmentosa-rp-due-to-mutations-in-exon-13-of-the-ush2a-gene-100564284","NCT06627179","Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","LUNA","Inclusion Criteria:\n\n1. An adult (≥18 years) willing and able to provide informed consent for participation prior to performing any study related procedures\n2. OR A minor (8 to \\\u003C18 years) able to provide age-appropriate assent for study participation with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures. An adult willing to comply with the protocol, follow study instructions, attend study visits as required and willing and able to complete all study assessments, in the opinion of the Investigator.\n\n   OR A minor able to complete all study assessments and comply with the protocol and has a parent or caregiver willing and able to follow study instructions and attend study visits with the subject as required, in the opinion of the Investigator.\n3. Both eyes exhibit clinical presentation consistent with RP involving Usher syndrome type 2 or NSRP based on ophthalmic, audiologic, or vestibular examinations. At screening, the Investigator will make the clinical diagnosis of \"Usher syndrome type 2a,\" defined as RP with congenital hearing loss, or \"non-syndromic RP,\" defined as RP without congenital hearing loss.\n4. A molecular diagnosis of biallelic disease causing variants (pathogenic or likely pathogenic) in the USH2A gene where at least one of the variants is located on exon 13. A historic genotyping report from a certified laboratory is acceptable with Sponsor approval.\n5. Clearly visible and measurable SD-OCT horizontal EZ width of ≥2.2 mm in both eyes based on the assessment of the CRC.\n6. BCVA ≥55 letters based on ETDRS (equivalent to 20\u002F80 based on Snellen notation, or logarithm of the minimum angle of resolution \\[logMAR\\] +0.6) in both eyes.\n7. Impairment of VF as assessed by SP with a mean sensitivity greater than 4 decibels (dB) and less than 25 dB measured by a V target size in the TE at screening.\n8. Mean sensitivity greater than 2 dB as determined by MP in the TE at screening.\n9. Symmetry of baseline disease in both eyes, defined as the mean BCVA (based on ETDRS) of one eye within ≤10 letters of the mean BCVA of the other eye at screening.\n\nExclusion Criteria:\n\n1. Presence of additional non-exon 13 USH2A pathogenic or likely pathogenic variant on the USH2A allele carrying the exon 13 mutation in subjects who have one exon 13 disease causing variant and one non-exon 13 disease causing variant.\n2. Presence of additional non-exon 13 USH2A pathogenic mutation(s) on both USH2A alleles in subjects who have biallelic exon 13 mutations.\n3. Presence of pathogenic or likely pathogenic variants in genes (other than the USH2A gene) which are known to be associated with other inherited retinal degenerative diseases or syndromes. Specifically, the presence of homozygous or compound heterozygous known disease-causing mutations in other genes involved in recessive retinal dystrophies, or the confirmed presence of a known single disease-causing variant in genes involved in dominant, X-linked, or mitochondrial retinal dystrophy genes is exclusionary.\n4. At screening, the EZ horizontal or vertical width are outside the field of the SD-OCT scan based on the assessment of the CRC.\n5. Presence of any significant ocular or non-ocular disease\u002Fdisorder (including medication and laboratory test abnormalities) which, in the opinion of the Investigator may either put the subject at risk because of participation in the study, may impact the subject's ability to participate in the study, or may interfere with assessment of efficacy and safety in the study.\n6. Presence of unstable concurrent cystoid macular edema (CME), or subject started on (or changed dose of) any medication for CME in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment). However, stable CME that disrupts the EZ width measurement, as determined by CRC, is an exclusion.\n7. Any intraocular surgery within 3 months of study entry or any planned intraocular or peri-ocular surgery during the study. Subjects may be eligible after 3 months post-surgery as long as they have fully recovered, in the opinion of the Investigator.\n8. Receipt of any IVT injection prior to study entry.","8 Years",{"count":252,"type":22},81,[254],"PHASE2","The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.",[257,258,259,29,72,74,260],"Retinitis Pigmentosa (RP)","Usher Syndrome Type 2","Deaf Blind","Vision Disorders",[111,258,259,262,263,264,265,266,267,248,268,269],"USH2A","RP","Exon 13","RNA therapies","antisense oligonucleotide","exon skipping","IVT","NSRP","2026-06-16",{"date":236,"type":43},{"date":273,"type":43},"2024-12-11",{"date":275,"type":22},"2027-12",{"name":93,"class":94},28,{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":16,"sex":17,"minAge":285,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":295,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":49},"100643002","collecting-data-on-retinal-blood-blood-flow-and-blood-vessel-shapeappearance-using-an-investigational-device-xycam-cre-and-to-then-compare-those-images-with-images-collected-from-a-patients-routine-clinical-examination-100643002","NCT07641738","Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape\u002FAppearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.","Evaluation of Patients With Retinal Disorders Utilizing the XyCAM CRE Camera.","Inclusion Criteria:\n\n* The Subject present to the ophthalmology\u002Foptometry clinic for eye examination. A signed\u002Fdated consent form has been obtained from a Subject who is capable of giving informed consent and compliant with the restrictions and requirements if the protocol.\n\nThe Subject is 21 years old with binocular vision.\n\nExclusion Criteria:\n\n* The Subject has significant media opacity (eg: a significant corneal scar) The Subject's medical history or health status suggests that the Subject may have an adverse reaction to administration of tropicamide or fluorescein dye.\n\nThe Subject has more than 15 dioptors of refractive error. The Subject is less that 21 years of age. The Subject is unable to follow instructions or otherwise unable to complete the study procedures.\n\nThe Subject has medical conditions such as nystagmus that will likely prevent the Subject from being able to hold their gaze steady during imaging, reducing the likelihood that high quality data can be acquired from the Subject.\n\nThe Subject is pregnant.","21 Years","100 Years",{"count":288,"type":22},350,"The primary objective of the XyCAM CRE Camera Study is to evaluate retinal blood flow, choroidal blood flow, and retinal structural features and their association with the progression and characterization of retinal diseases using the XyCAM CRE Camera. The XyCAM CRE is an investigational, noninvasive optical imaging instrument manufactured by Vasoptic Medical, Inc.\n\nXyCAM CRE imaging data will be collected and compared with established retinal imaging modalities currently used in ophthalmic clinical practice, including Color Fundus Photography (CFP), Optical Coherence Tomography (OCT), Optical Coherence Tomography Angiography (OCTA), and Fluorescein Angiography (FA). Imaging data obtained from XyCAM CRE and reference modalities will be assessed to investigate correlations, agreement, and differences between measurements in order to evaluate the potential of XyCAM CRE to provide complementary diagnostic and disease management information in retinal disease.\n\nSecondary objectives of the study include:\n\nComparing image quality and image-derived information obtained from XyCAM CRE with other clinical reference imaging modalities across different operators and a diverse study population representative of the general population; Investigating the relationship between XyCAM CRE imaging data and established clinical indicators of glaucoma, macular degeneration, hypertensive retinopathy, diabetic retinopathy, inherited retinal disease, and retinal vascular disease.",[291,29],"Microvascular Disease",[293,294],"XyCAM CRE","XyCAM RI","NOT_YET_RECRUITING","2026-06-06",{"date":298,"type":43},"2026-06-11",{"date":300,"type":22},"2026-06-15",{"date":302,"type":22},"2030-06-15",{"name":304,"class":218},"Stuart Terry Eye Associates",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":17,"minAge":311,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":49},"100638948","establishment-of-a-multimodal-standard-database-for-inflammation-related-ophthalmopathy-100638948","NCT07628946","Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy","Inclusion Criteria:\n\n1. Retinal vascular and metabolic-related diseases: Diabetic Retinopathy (DR, including NPDR and PDR), Retinal Vein Occlusion (RVO), Hypertensive Retinopathy.\n2. Degenerative diseases: Age-related Macular Degeneration (including dry and wet forms), Pathologic Myopia (PM), Polypoidal Choroidal Vasculopathy (PCV).\n3. Immune-mediated and inflammatory eye diseases: Uveitis (including primary and secondary), Optic Neuritis, Mooren's Ulcer, and corneal melting associated with systemic immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n4. Anterior segment and ocular surface syndromes: Various types of Dry Eye Disease (DED), Keratoconus, Glaucoma (especially cases with chronic inflammation or long-term medication use).\n5. Developmental fundus diseases in children and adolescents: Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP).\n6. Patients with a confirmed diagnosis of fundus diseases, including Diabetic Retinopathy, Pathologic Myopia, Age-related Macular Degeneration, Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP), and other adult or pediatric fundus diseases.\n7. Ability to cooperate with study examinations, including acceptance of Ultra-Widefield (UWF) fundus photography, OCT\u002FOCTA, AOSLO, corneal confocal microscopy, meibomian gland function assessment, corneal esthesiometry, and tear film function tests. Image quality must meet analytical standards.\n8. Availability of complete or follow-up accessible ophthalmic medical records.\n9. Blood pressure ≤ 160\u002F100 mmHg (to avoid exacerbating ischemia due to uncontrolled hypertension).\n\nExclusion Criteria:\n\n1. Recent (within the past 3 months) corneal\u002Fconjunctival acute inflammation, ocular surgery, or ocular trauma; or presence of corneal alterations (e.g., contact lens wear).\n2. Fundus images that are uninterpretable or severely obscured (e.g., vitreous hemorrhage).\n3. Use of medications affecting tear secretion (e.g., antihistamines, antidepressants) within the past 30 days.","3 Years",{"count":313,"type":22},3000,"Through a systematic observational study, the intrinsic connections and patterns between the occurrence and development of common blinding retinal diseases such as diabetic retinopathy, pathological myopia, and age-related macular degeneration and the changes in fine parameters of the anterior structure of the eye are deeply explored. To achieve this goal, investigators will adopt cutting-edge multimodal imaging technology to simultaneously collect precise data from ocular surface and fundus of participants. By integrating and analyzing these multi-dimensional information from different parts of the same eye, investigators will build a high-quality and standardized ocular surface-fundus associated image database. This database not only aims to reveal potential ocular surface biomarkers that can be used for early warning or auxiliary diagnosis, but also lays a solid data foundation for the future development of artificial intelligence-assisted diagnostic tools and the establishment of a brand-new ocular surface-fundus integrated diagnosis and treatment assessment model.",[316,317,29,318],"Ocular Surface Disease","Inflammatory Disease","Choroid Diseases","2026-06-01",{"date":321,"type":43},"2026-06-05",{"date":323,"type":43},"2025-11-26",{"date":325,"type":22},"2030-02",{"name":327,"class":218},"Dan Chen",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":336,"targetDuration":338,"studyType":23,"phases":4,"briefSummary":339,"conditions":340,"keywords":361,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":49},"100242565","inherited-retinal-degenerative-disease-registry-100242565","NCT02435940","Inherited Retinal Degenerative Disease Registry","Foundation Fighting Blindness My Retina Tracker Registry","MRTR","Inclusion Criteria:\n\n* Diagnosed with an inherited retinal degenerative disease OR\n\nExclusion Criteria:\n\n* Glaucoma only\n* Diabetic retinopathy only\n* Non-retinal disease\n* Not heritable retinal disease",{"count":337,"type":22},20000,"20 Years","The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.",[341,29,342,343,344,345,234,346,347,145,147,348,349,350,351,352,353,354,68,355,111,356,357,146,358,359,112,360],"Eye Diseases Hereditary","Achromatopsia","Bardet-Biedl Syndrome","Bassen-Kornzweig Syndrome","Batten Disease","Choroidal Dystrophy","Choroideremia","Congenital Stationary Night Blindness","Enhanced S-Cone Syndrome","Fundus Albipunctatus","Goldmann-Favre Syndrome","Gyrate Atrophy","Juvenile Macular Degeneration","Kearns-Sayre Syndrome","Refsum Syndrome","Retinitis Punctata Albescens","Retinoschisis","Rod Dystrophy","Rod Monochromacy","Usher Syndrome",[362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389],"inherited retinal degenerative disease","retinitis pigmentosa","Usher","Leber","Bardet-Biedl","Batten","Best","cone dystrophy","cone-rod dystrophy","choroideremia","congenital night blindness","enhanced s-cone","cone monochromacy","Goldmann-Favre","Kearns-Sayre","Refsum","retinoschisis","rod-cone dystrophy","rod dystrophy","rod monochromacy","Sorsby pseudoinflammatory dystrophy","stargardt","achromatopsia","juvenile inherited macular degeneration","cone dichromacy","cone trichromacy","Charcot-Marie-Tooth","albipunctate dystrophy","2026-05-18",{"date":392,"type":43},"2026-05-19",{"date":394,"type":4},"2014-06",{"date":396,"type":22},"2037-06",{"name":398,"class":218},"Foundation Fighting Blindness",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":61,"phases":408,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":49},"100545297","comparison-of-clarus-and-optos-ultrawide-field-imaging-systems-for-inherited-retinal-disease-100545297","NCT06380075","COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease","COCO-IRD","Inclusion Criteria:\n\n* Participants 18 years and older with a clinical and\u002F or genetic diagnosis of IRD recruited either from the clinic and\u002For the Inherited Ocular Disease Registry to participate in this trial\n* Participants that are willing to participate as evidenced by signing the written informed consent\n\nExclusion Criteria:\n\n* Presence of ocular conditions other than an IRD which may affect the quality of ocular imaging including but not limited to advanced cataracts, corneal disorders, nystagmus, vitreous hemorrhage, or poor dilation\n* Presence of ocular conditions other than an IRD which may affect interpretation of retinal imagining including but not limited to epiretinal membrane, choroidal neovascular membrane, or macular scarring\n* Patients with advanced IRDs who are unable to fixate for imaging\n* Patients unable to tolerate ocular imaging\n* Patients who do not wish to participate",{"count":407,"type":22},50,[108],"The goal of this research study is to compare two ultrawide field cameras to the gold standard imaging system to evaluate the back of the eye. The main question it aims to answer is the same results and information can be acquired from all of the cameras for evaluating and monitoring inherited retinal diseases (IRDs).\n\nParticipants will:\n\n* undergo pupillary dilation\n* have photographs taken of the inside of the eyes using three different cameras",[29],"2026-04-22",{"date":413,"type":43},"2026-04-24",{"date":415,"type":43},"2024-08-29",{"date":417,"type":22},"2026-12",{"name":419,"class":218},"University of Wisconsin, Madison",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":61,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":295,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":49},"100496926","phase-3-safety-and-tolerability-of-irx-101-in-patients-receiving-intravitreal-injections-100496926","NCT05750589","Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections","Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy","COMFORT","Inclusion Criteria:\n\n1. Capable of giving informed consent\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes\n\nExclusion Criteria:\n\n1. Current or past diagnosis of endophthalmitis\n2. Current diagnosis of uveitis\n3. Monocular patients (vision 20\u002F100 or worse in one eye) who are receiving injections in the better seeing eye\n4. Current use of viscous lidocaine products for ocular anesthesia prior to IVT\n5. Currently receiving intravitreal steroid injections\n6. Concurrent participation in another clinical trial\n7. Females who are pregnant, planning to become pregnant or lactating",{"count":429,"type":22},240,[63],"This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.",[29],"2026-03-30",{"date":435,"type":43},"2026-04-03",{"date":437,"type":22},"2026-09-01",{"date":439,"type":22},"2027-12-31",{"name":441,"class":94},"iRenix Medical, Inc.",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":16,"sex":17,"minAge":448,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":61,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":460,"leadSponsor":462,"locationsCount":49},"100580766","advancing-pediatric-retinal-imaging-with-auto-aligned-oct-100580766","NCT06841575","Advancing Pediatric Retinal Imaging With Auto-aligned OCT","Inclusion Criteria:\n\n* Group 1: Healthy adult volunteers\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age\n* Healthy adult volunteers without known ocular issues other than refractive error\n* Group 2: Adult patients in ophthalmology clinics\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the subject\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age and is a patient in the Duke Eye Center ophthalmology clinics\n* Group 3: Pediatric participants in ophthalmology clinics\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent\u002Flegal guardian\n* Parent\u002Flegal guardian is able and willing to consent to study participation\n* Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center\n\nExclusion Criteria:\n\n* Group 1: Healthy adult volunteers\n* Students or employees under direct supervision of the investigators\n* Subjects with prior problems with pupil dilation\n* Pregnant woman if receiving dilating drops\n* Group 2: Adult patients in ophthalmology clinics\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)\n* Group 3: Pediatric participants in ophthalmology clinics\n* Parent\u002Flegal guardian unwilling or unable to provide consent\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)","1 Month",{"count":407,"type":22},[108],"The goal of the current study is to conduct a pilot study to test a new version of the handheld OCT device capable of auto-alignment to image the retina in adult volunteers, and adult and pediatric patients in clinic.",[73,29,117,453],"Optic Nerve Diseases",[455],"Optical Coherence Tomography (OCT)","2026-03-23",{"date":458,"type":43},"2026-03-25",{"date":456,"type":43},{"date":461,"type":22},"2027-09",{"name":463,"class":218},"Duke University",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":11,"sex":17,"minAge":472,"maxAge":473,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":476,"conditions":477,"keywords":480,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":49},"100628198","longitudinal-observational-study-of-diabetic-retinopathy-progression-in-type-2-diabetes-patients-100628198","NCT07458516","Longitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients","IMaging Pre-PrOlifeRative sTAge of Diabetic retiNopaThy to Guarantee Timely Treatment - IMPORTANT","IMPORTANT","Inclusion Criteria:\n\n* Type 2 diabetes mellitus (T2D) according to 1985 World Health Organization (WHO) criteria.\n* Age between 35 and 80 years.\n* Best-corrected visual acuity (BCVA) ≥ 69 letters (20\u002F40).\n* Refraction with a spherical equivalent less than 5 diopters.\n* Non-proliferative diabetic retinopathy (NPDR; DRSS levels 43, 47, 53) or mild proliferative diabetic retinopathy (PDR; DRSS level 61: Neovascularization Elsewhere (NVE) \\\u003C ½ disc area in ≥ 1 quadrant, no Neovascularization of the Disc (NVD), no vitreous or sub-hyaloid hemorrhage), in which panretinal photocoagulation (PRP) and\u002For intravitreal anti-VEGF treatment can safely be deferred for at least 6 months, based on consensus between patient and investigator - using ETDRS criteria, 7-field equivalent area on ultra-widefield fundus imaging.\n* Ability to understand and sign the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Central subfield thickness (CST) \\> 400 μm (fluid allowed if CST ≤ 400 μm and foveal contour is normal, as determined by the Central Reading Centre, and treatment is not immediately required).\n* Any sign of retinal fibrovascular proliferation.\n* Uncontrolled glaucoma (intraocular pressure \\> 25 mmHg regardless of concomitant IOP-lowering medications) or neovascular glaucoma.\n* Any sign of iris neovascularization, vitreous, or pre-retinal hemorrhage.\n* Other retinal vascular diseases (ocular ischemic syndrome, retinal arterial or venous occlusion, exudative age-related macular degeneration, etc.).\n* Previous panretinal photocoagulation (PRP) or intravitreal injection treatment.\n* Any eye surgery within 6 months prior to the inclusion visit.\n* Significant media opacities including severe cataract, corneal scarring or edema, or vitreous hemorrhage that precludes fundus evaluation.\n* Pupil dilation \\\u003C 5 mm.","35 Years","80 Years",{"count":475,"type":22},100,"The purpose of this clinical study is to explore imaging, functional and systemic biomarkers of diabetic retinopathy (DR) progression, in Type 2 Diabetes (T2D) patients with moderate to severe non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR) using state of the art methodologies, commonly applied in clinical practice, over a period of two years. This study will provide longitudinal data to better understand retinal changes in moderate to severe diabetic retinopathy and early proliferative diabetic retinopathy and help guide timely interventions to prevent vision loss.",[27,478,479,29],"Diabetes Mellitus, Type 2","Diabetic Complication",[481],"Disease biomarkers","2026-03-09",{"date":484,"type":43},"2026-03-11",{"date":486,"type":43},"2025-11-24",{"date":488,"type":22},"2028-06",{"name":490,"class":218},"Association for Innovation and Biomedical Research on Light and Image",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":61,"phases":501,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":295,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":49},"100623809","a-multimodal-ai-agent-for-ophthalmic-clinical-decision-support-100623809","NCT07401459","A Multimodal AI Agent for Ophthalmic Clinical Decision Support","Multicenter Randomized Controlled Trial of a Multimodal AI Agent for Ophthalmology Clinical Decision Support","Inclusion Criteria:\n\n1. Outpatient participants aged 6 to 75 years.\n2. Participants who undergo ophthalmic examinations for medical purposes during the study period.\n3. Participants who can produce clear ophthalmic images in both eyes.\n4. Agree to participate in this study with written informed consent:\n\n   1. Participants aged 18 years or older provide their own consent.\n   2. Participants aged 6-17 years require consent from a parent or legal guardian.\n\nExclusion Criteria:\n\n1. Participants who are reluctant to participate in this study.\n2. Participants presenting with acute or emergency ocular conditions requiring immediate intervention.\n3. Participants with poor quality of ophthalmic images, including blurriness, artifacts, underexposure, or overexposure.\n4. Other unsuitable reasons determined by the evaluators.","75 Years",{"count":500,"type":22},300,[108],"This study is a multicenter randomized controlled trial evaluating the effectiveness and safety of EyeAgent, a multimodal artificial intelligence (AI) agent designed to assist ophthalmologists in clinical decision-making. Participants will be recruited from ophthalmology clinics and hospitals in Hong Kong and mainland China. The AI agent acts as a digital co-pilot, analyzing patient images and clinical history to provide diagnostic and management recommendations. The trial aims to determine whether the use of the AI agent improves diagnostic accuracy, treatment decision-making performance, report generation, workflow efficiency, and user satisfaction compared to standard clinical practice.",[133,504,505,132,29],"Large Language Models","AI Agent",[507,508,509,510,511,512],"medical AI agent","large language model","ophthalmology","tool integration","clinical decision support","real world study","2026-02-19",{"date":515,"type":43},"2026-02-23",{"date":517,"type":22},"2026-03-01",{"date":519,"type":22},"2026-12-31",{"name":521,"class":218},"The Hong Kong Polytechnic University",{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":16,"sex":17,"minAge":528,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":166},"100604455","data-gathering-for-a10900-100604455","NCT07149740","Data Gathering for A10900","Inclusion\u002FExclusion Criteria Inclusion Criteria for Retinal Disease Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. BCVA 20\u002F400 or better in the study eye\n4. Participants presenting at the site with retinal disease\n5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others\n\nExclusion Criteria for Retinal Disease Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons\n3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and\u002For investigator assessment at the study visit;\n\nInclusion Criteria for Glaucoma Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. BCVA 20\u002F40 or better in the study eye\n4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:\n\n   1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;\n   2. Glaucoma hemi-field test \"outside normal limits.\"\n5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:\n\n   1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;\n   2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue\n\nExclusion Criteria for Glaucoma Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons\n3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses \\> 33% or false positives \\> 33%, or false negatives \\> 33% in the study eye\n5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group\n\n1\\. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.\n\nExclusion Criteria for Corneal Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images.\n\nInclusion Criteria for Normal Group\n\n1. Participants 22 years of age or older on the date of informed consent\n2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent\n3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).\n4. BCVA 20\u002F40 or better (each eye)\n5. Participant is able to comply with the study procedures\n\nExclusion Criteria for Normal Group\n\n1. Participants unable to tolerate ophthalmic imaging\n2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study\n3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images\n4. History of leukemia, dementia or multiple sclerosis","22 Years",{"count":530,"type":22},180,"The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes",[29,533,117,534],"Healthy","Corneal Diseases","2026-02-11",{"date":537,"type":43},"2026-02-13",{"date":539,"type":43},"2025-06-26",{"date":541,"type":22},"2026-05-01",{"name":543,"class":94},"Optos, PLC",{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":61,"phases":553,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":49},"100593454","chopxe---analysis-of-choriocapillaris-flow-deficits-in-patients-with-pseudoxanthoma-elasticum-100593454","NCT07006649","CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum","CHOPXE","Inclusion Criteria:\n\n* Participant not afflicted by the disease under investigation and without ophthalmological pathology\n* Person matched in age (+\u002F- 5 years) and gender to a case (patient with PXE in pre-atrophic stages included in the PXE cohort)\n* Signature of informed consent for participation in the protocol\n* Adult at time of inclusion Criteria for non-inclusion of research subjects\n* Known ophthalmological diseases (maculopathy, glaucoma, optic neuropathy, retinopathy whatever the aetiology)\n* Known severe myopia, defined by a sphere \\> - 6 dioptres\n* Diabetic subject\n* Unable to carry out the ophthalmological examinations of the study\n* Pregnant, breast-feeding or parturient woman\n* Person undergoing psychiatric care under constraint\n* Person subject to a legal protection measure\n* Person not affiliated or not benefiting from a social security scheme\n\nExclusion Criteria:\n\n* Ophthalmic pathology (maculopathy, glaucoma, optic neuropathy, retinopathy, whatever the etiology) discovered during the ophthalmic workup\n* AngioOCT examination inexploitable (artifact and\u002For image quality less than 50\u002F100 even after pupillary dilation)\n* Severe myopia (sphere \\> - 6 dioptres) discovered during the ophthalmic workup.\n\nCase inclusion critera :\n\n* Patient diagnosed with pseudoxanthoma elasticum, defined according to Plomp's criteria: two out of three features related to PXE: (1) two pathogenic mutations in the ABCC6 gene, and\u002For (2) disease-specific dermatological changes and\u002For (3) disease-specific ocular changes;\n* Included in the PXE cohort ;\n* With pre-atrophic damage, i.e. at least one eye without choroidal neovessels on OCT-A, without previous intravitreal injection of anti-VEGF, and without major retinal atrophy (less than 2 papillary diameters);\n* who have had an angiographic OCT (performed during follow-up consultations) with usable results (no artifacts and image quality of 50\u002F100 or better) ;\n* patient's non-objection to participation in a study\n\nCase criteria for non-inclusion :\n\n* Other known ophthalmological pathology (maculopathy, glaucoma, optic neuropathy, retinopathy of any etiology)\n* Severe myopia, defined by a sphere \\> - 6 dioptres\n* Diabetic subject",{"count":552,"type":22},60,[108],"This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum. Pseudoxanthoma elasticum (PXE) is a rare, incurable hereditary disease caused by genetic mutations. The condition is characterised by excessive tissue mineralisation, which can result in a range of dermatological, vascular, and ophthalmological complications. Among these complications is the potential for visual impairment. The management of this condition is focused on the treatment of its complications. Degeneration of the retina and the choroid (the layer responsible for ensuring its vascularisation) occurs in the eye, resulting in premature degeneration. We would like to study the premature alteration of these structures, which could subsequently be used as an objective marker of the evolution of pseudoxanthoma elasticum.",[556,557,29],"Pseudoxanthoma Elasticum","Tomography, Optical Coherence",[559,560,561,562,563],"comparative studies","observational study","adult","cross-sectional studies","healthy volunteers","2025-12-01",{"date":566,"type":43},"2025-12-08",{"date":568,"type":43},"2025-11-28",{"date":570,"type":22},"2026-11",{"name":572,"class":573},"University Hospital, Angers","OTHER_GOV",{"id":575,"slug":576,"hasResults":11,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":16,"sex":17,"minAge":582,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":585,"conditions":586,"keywords":594,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":49},"100340496","intraoperative-oct-guidance-of-intraocular-surgery-ii-100340496","NCT03713268","Intraoperative OCT Guidance of Intraocular Surgery II","Intraoperative OCT Guidance of Intraocular Surger","MIOCT","Inclusion Criteria:\n\n1. Healthy controls: Healthy eyes without known disease: refractive error including myopia and non-significant cataract is allowed. For selected testing pseudophakia is allowed.\n2. Surgeons as research subjects: Adult (≥18 years old)\n3. Surgical patients (vitreoretinal surgery): Patients undergoing examination under anesthesia or surgery for vitreoretinal diseases\n4. Surgical patients (anterior segment surgery-glaucoma, ocular surface or strabismus requiring extraocular muscle surgery): Include both adults and children. Patient undergoing primary, elective minimally invasive glaucoma surgery, ocular surface surgery, or strabismus surgery.\n\nExclusion Criteria:\n\n1. Healthy controls: Any ocular disease that restricts the ability to perform OCT scanning. Conflict of interest with investigators\u002Fstudy personnel, e.g. a student in the lab of an investigator.\n2. Surgeons as research subjects: no specific exclusion criteria.\n3. Surgical patients (vitreoretinal surgery): Neonates (\\\u003C 4 weeks of age) and patients with any ocular disease that restricts the ability to perform OCT scanning.\n4. Surgical patients (anterior segment surgery-corneal and cataract diseases): Pediatric patients: The cornea and cataract surgery studies will be restricted to adults (≥ 18 years). Children do not have cataract surgery typically by residents and therefore would not fit our study design. Similarly pediatric corneal transplants are very rare.","4 Weeks",{"count":584,"type":22},262,"The overall five-year goals of the project are to develop novel technology to provide actionable new information through provision of live volumetric imaging during surgery, improving surgical practice and outcomes. The investigators believe this technology will enable novel ophthalmic and other microsurgeries not possible due to current limitations in surgical visualization.",[587,588,27,589,29,590,591,592,593,533],"Macular Holes","Epiretinal Membrane","Retinal Detachment","Preretinal Fibrosis","Cataract","Ocular Tumor","Strabismus",[595,580,596,597],"Microscope Integrated optical coherence tomography","OCT Angiography","OCTA","2025-10-02",{"date":600,"type":43},"2025-10-06",{"date":602,"type":43},"2018-09-30",{"date":604,"type":22},"2027-05-31",{"name":463,"class":218},{"id":607,"slug":608,"hasResults":11,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":615,"conditions":616,"keywords":617,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":624,"locationsCount":49},"100526805","optimize-pediatric-oct-imaging-100526805","NCT06139523","Optimize Pediatric OCT Imaging","Optimize Pediatric OCT (Optical Coherence Tomography) Imaging: a Pilot Study","Inclusion Criteria:\n\n* Group 1 - Healthy adult volunteers\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age\n* Healthy adult volunteers without known ocular issues other than refractive error\n* Pregnancy Reasonably Excluded Guide (PREG) evaluation on women of childbearing potential\n* Group 2 - Pediatric participants\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent\u002Flegal guardian\n* Parent\u002Flegal guardian is able and willing to consent to study participation\n* Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center\n\nExclusion Criteria:\n\n* Group 1 - Healthy adult volunteers\n* Students or employees under direct supervision of the investigators\n* Subjects with prior problems with pupil dilation\n* Pregnant woman if receiving dilating drops\n* Group 2 - Pediatric participants\n* Parent\u002Flegal guardian unwilling or unable to provide consent\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)",{"count":614,"type":22},30,"Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina.\n\nThe investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).",[29,117,453],[455],"2025-09-16",{"date":620,"type":43},"2025-09-17",{"date":622,"type":43},"2024-01-24",{"date":417,"type":22},{"name":463,"class":218},{"id":626,"slug":627,"hasResults":11,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":61,"phases":634,"briefSummary":635,"conditions":636,"keywords":639,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":49},"100539559","phase-3-a-efficacy-and-safety-study-of-ranibizumab-10mgml-injection-incepta-in-patients-with-diabetic-macular-edema-100539559","NCT06305416","A Efficacy and Safety Study of Ranibizumab 10mg\u002Fml Injection (Incepta) in Patients With Diabetic Macular Edema","Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg\u002Fml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection","Inclusion Criteria:\n\n1. Ages Eligible for Study: ≥ 18 Years\n2. Ability to provide written informed consent and comply with study assessments for the full duration of the study\n3. Diagnosis of diabetes mellitus (type 1 or 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: Laboratory reports that prove DM of patient or current regular use of insulin for treatment of diabetes or current regular use of oral anti-hyperglycemic agent for the treatment of diabetes.\n4. Clinical evidence of retinal thickening due to macular edema involving the center of the macula (can be associated with diabetic retinopathy)\n5. Central diabetic macular edema present on clinical examination and OCT testing with central 1mm sub field thickness greater than 300 microns as measured on -OCT\n6. Visual acuity score greater than or equal to 19 letters (20\u002F400) and less than or equal to 73 letters (20\u002F40) by the ETDRS\u002F Snellen chart visual acuity protocol\n7. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography\n8. Willingness and ability to undertake all scheduled visits and assessments\n\nExclusion Criteria:\n\n1. Prior treatment with any Intravitreal drug, Bevacizumab, verteporfin or photodynamic therapy (except for extra foveal laser photocoagulation) in the study eye within past 3 months before study entry\n2. Laser photocoagulation in the study eye within 1 month before study entry\n3. Participation in another ocular investigation or trial simultaneously\n4. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.\n5. Blood pressure \\> 160\u002F100 mmHg (systolic above 160 or diastolic above 100) and Random Blood Sugar (RBS) ≥ 12 mmol\u002FL and\u002F or HbA1c ≥ 7.5%\n6. Evidence of vitreoretinal interface abnormality and optic nerve disease after ocular exam or OCT that may be contributing to the macular edema\n7. Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the study period or that could contribute to a loss of best corrected visual acuity over the study period (e.g. cataract that might decrease the vision by 3 or more lines, uncontrolled glaucoma, uveitis, previous corneal transplant etc.). The decision regarding exclusion is to be based on the opinion of the investigator.\n8. An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of sub retinal fibrosis or geographic atrophy).\n9. Presence of suspected ocular or periocular infections, another ocular condition that may affect the visual acuity or macular edema during the course of the study (uveitis, Irvine-Gas)\n10. Vitreous hemorrhage preventing visualization of retina\n11. History of vitreous surgery, cataract surgery, YAG capsulotomy in the study eye within last 3 months of enrolment\n12. Visual acuity \\\u003C20\u002F400 in the fellow eye\n13. Known hypersensitivity to Ranibizumab or any of the components of study medication\n14. History of cerebral vascular accident or myocardial infarction within past 3 months.\n15. Employees of Investigational sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.\n16. Current use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine\u002F hydroxychloroquine, tamoxifen, phenothiazine, vigabatrin and ethambutol, and such medications will not be allowed during the study period.",{"count":633,"type":22},70,[63],"Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema.\n\nDiabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus.\n\nThe use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.",[637,27,638,124,29,232],"Diabetic Macular Edema","Macular Edema",[640,641,642,135,643],"Ranibizumab","Efficacy","Diabetes","Edema","2025-06-03",{"date":646,"type":43},"2025-06-06",{"date":648,"type":43},"2024-03-30",{"date":650,"type":22},"2025-12",{"name":652,"class":94},"Incepta Pharmaceuticals Ltd",{"id":654,"slug":655,"hasResults":11,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":4,"eligibilityCriteria":659,"healthyVolunteers":11,"sex":17,"minAge":660,"maxAge":286,"enrollmentInfo":661,"targetDuration":4,"studyType":61,"phases":663,"briefSummary":665,"conditions":666,"keywords":667,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":219},"100546384","phase-1-safety--efficacy-of-eyecyte-rpe-in-patients-with-geographic-atrophy-secondary-to-dry-age-related-macular-degeneration-100546384","NCT06394232","Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.","A Phase 1\u002F2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","Inclusion Criteria:\n\n1. Men and women ≥ 50 years of age at Screening.\n2. Diagnosis of Geographic Atrophy secondary to d-AMD\n3. Have Best Corrected Visual Acuity (BCVA) equal to or less than 20\u002F200 Snellen (ETDRS letter score ≤ 35) in the study eye at screening.\n\n   1. Phase 1 ≤ 20\u002F200 and\n   2. Phase 2a ≥ 20\u002F64 (ETDRS letter score 60) in the study eye at Screening.\n4. Vision in the unoperated eye must be better or equal to vision in the study eye.\n5. Willing, committed, and able to return for ALL clinic visits and complete all study related procedures.\n6. Be medically suitable to undergo anesthesia, vitrectomy and subretinal injection in the opinion of the Investigator.\n7. Be medically suitable for immunosuppression therapy in accordance with the requirements of this protocol in the opinion of the Investigator.\n8. Able to read (or if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) and understand, and willing to sign the informed consent form (ICF)\n9. Willing to provide signed Informed Consent prior to any procedures being performed at Visit 1, Screening.\n10. Negative for HIV, HbsAg, HCV, TB\n11. The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:\n\n    1. Total GA area must be ≥ 1.25 and ≤ 17.5 mm2 (0.5 and 7 disk areas \\[DA\\] respectively)\n    2. The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.\n    3. At least one of the lesions has to be sub-foveal.\n\nExclusion Criteria:\n\n1. Have evidence of neovascular AMD in either eye by clinical examination, fluorescein angiography or optical coherence tomography.\n2. Have GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like Chloroquine maculopathy in either eye.\n3. Have any evidence of active or inactive choroidal neovascularization (CNV) due to other causes such as ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, uveitis, punctate inner choroidopathy, or multifocal choroiditis in the study eye.\n4. Axial myopia greater than -6 diopters or axial length more than 26 mm.\n5. Have a decrease in BCVA in the study eye due to causes other than GA (e.g., pigment abnormalities, dense sub foveal hard exudates, previous vitreoretinal surgery, retinal dystrophies, non-retinal conditions, visually significant cataract, macular ischemia, etc.).\n6. Have the presence of retinal pigment epithelial tears or rips involving the macula in the study eye at screening.\n7. Have a history or evidence of vitreous hemorrhage in the study eye.\n8. Have a history or clinical evidence of severe diabetic retinopathy, diabetic macular edema, retinal vein occlusion or any other vascular disease affecting the retina in the study eye.\n9. Have had a prior pars plana vitrectomy in the study eye.\n10. Have a history of retinal detachment or treatment or surgery for retinal detachment in the study eye.\n11. Have history of a macular hole in the study eye.\n12. Have had any other ocular surgery (except cataract) within 2 months or Yttrium Aluminum Garnet (YAG) laser capsulotomy in the study eye in the past 4 weeks.\n13. Have had a prior trabeculectomy or other filtration surgery in the study eye.\n14. History of any form of glaucoma in the study eye.\n15. Patients with ocular pathology, particularly that of retina (other than AMD).\n16. Have active intraocular inflammation or a history or evidence of uveitis in either eye.\n17. Have active ocular or periocular infection in either eye, or a history of any ocular or periocular infection within the 2 weeks prior to Visit 1, Screening in either eye.\n18. Have a history of scleromalacia in either eye.\n19. Have had previous therapeutic radiation in the study eye.\n20. Have a history of corneal transplant or corneal dystrophy.\n21. Have any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.\n22. Have a history of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications.\n23. Have participated as a subject in any clinical study within 6 months prior to Day 0, Baseline.\n24. Have a known serious allergy to fluorescein sodium for injection in angiography, Povidone Iodine or any of the other medications required for anesthesia or the subretinal injection procedure.\n25. Be a female who is pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study at Screening and Baseline.\n26. Currently receiving aspirin, aspirin containing products and\u002For any other coagulation modifying drugs which cannot be discontinued 7 days prior to surgery.\n27. Have any systemic condition that would qualify the subject as being immunocompromised (e.g., severely uncontrolled diabetes, cancer).\n28. Patients with Optic Atrophy","50 Years",{"count":662,"type":22},54,[664,254],"PHASE1","The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).\n\nThe main questions it aims to answer are:\n\n* Safety and tolerability of the novel stem cell formulation\n* Potential efficacy of the novel stem cell formulation\n\nParticipants will receive a single subretinal injection in their study eye and followed up for safety.\n\nThis is an India only study and the product is developed indigenously.",[29,124,26,138,73],[136,138,668,669,670,671],"Visual Impairment","Subretinal injection","Stem cells","Retinal Pigment Epithelial Cells","2024-09-23",{"date":674,"type":43},"2024-09-24",{"date":676,"type":43},"2024-06-04",{"date":678,"type":22},"2030-12",{"name":680,"class":94},"Eyestem Research Pvt. Ltd.",{"id":682,"slug":683,"hasResults":11,"nctId":684,"briefTitle":685,"officialTitle":685,"acronym":4,"eligibilityCriteria":686,"healthyVolunteers":11,"sex":17,"minAge":687,"maxAge":104,"enrollmentInfo":688,"targetDuration":4,"studyType":61,"phases":689,"briefSummary":691,"conditions":692,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":701,"lastUpdatePostDateStruct":702,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":49},"100556078","phase-4-safety-and-efficacy-of-18-mm-short-vitrectomy-probe-for-pediatric-vitreoretinal-surgeries-100556078","NCT06520410","Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries","Inclusion Criteria:\n\n* Patients less than 18 years old\n* Need vitrectomy due to various etiologies, including retinopathy of prematurity, familial exudative vitreoretinopathy, persistent fetal vasculature, congenital cataract, lens dislocation, open-globe injury, vitreous hemorrhage, or other vitreoretinal diseases.\n\nExclusion Criteria:\n\n* Patients who cannot cooperate fully with detailed ophthalmic examinations.","0 Years",{"count":552,"type":22},[690],"PHASE4","This study aims to study the safety and efficacy of using an 18 mm short vitrectomy probe for pediatric vitreoretinal surgeries and to investigate the surgeon's comfort and reliability of using the shorter probe.",[693,29,694,695,696,697,698,699,700],"Retinopathy of Prematurity Both Eyes","Persistent Fetal Vasculature","Coats Disease","Coats Retinopathy","Familial Exudative Vitreoretinopathies","Vitreous Disorder","Vitreous Anomalies","Retinal Vascular Disorder","2024-07-21",{"date":703,"type":43},"2024-07-25",{"date":705,"type":43},"2024-03-05",{"date":707,"type":22},"2028-02-28",{"name":709,"class":218},"Chang Gung Memorial Hospital",{"id":711,"slug":712,"hasResults":11,"nctId":713,"briefTitle":714,"officialTitle":715,"acronym":4,"eligibilityCriteria":716,"healthyVolunteers":11,"sex":17,"minAge":338,"maxAge":660,"enrollmentInfo":717,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":719,"conditions":720,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":49},"100492972","perfluorooctyl-bromide-which-empowers-the-liquid-to-flat-the-detached-retina-and-displace-the-underneath-fluids-anteriorly-100492972","NCT05699096","Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anteriorly","Perfluorooctyl Bromideessential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset","Inclusion Criteria:\n\n* \\- Is 20 years or older Has been diagnosed with Keratoconus; Has no other active ocular disease; Is not pregnant or nursing;\n\nExclusion Criteria:\n\n* Is under the age of 20 Has best corrected visual acuity outside 20\u002F400; Pregnant or nursing at the time of enrollment in the study;",{"count":718,"type":22},20,"Perfluorohexyloctaneis Essential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset",[29],"2024-06-30",{"date":723,"type":43},"2024-07-03",{"date":725,"type":22},"2024-09-01",{"date":727,"type":22},"2026-07-01",{"name":729,"class":94},"EL Romany Ophthalmics Factory",{"id":731,"slug":732,"hasResults":11,"nctId":733,"briefTitle":734,"officialTitle":735,"acronym":4,"eligibilityCriteria":736,"healthyVolunteers":16,"sex":17,"minAge":338,"maxAge":4,"enrollmentInfo":737,"targetDuration":227,"studyType":23,"phases":4,"briefSummary":739,"conditions":740,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":705,"lastUpdatePostDateStruct":741,"startDateStruct":743,"completionDateStruct":745,"leadSponsor":746,"locationsCount":49},"100538193","color-fundus-photograph-with-experts-labelling-100538193","NCT06287645","Color Fundus Photograph With Experts Labelling","Development of Digital Fundus Images Dataset of Local Population of Pakistan","Inclusion Criteria:\n\n* Patients with Type I or Type II Diabetes.\n* Patients of age of 20 years or above\n\nExclusion Criteria:\n\n* The participant is unable or unwilling to comply with study procedures.\n* Vulnerable participants (minors, legally detained individuals).\n* Prisoners or subjects who are involuntarily incarcerated.",{"count":738,"type":22},50000,"This trial aims to provide a digital retinal image dataset from Pakistan, graded by three specialists according to the severity of Diabetic Retinopathy. The dataset aims to improve research and patient care.",[29,27],{"date":742,"type":43},"2024-03-07",{"date":744,"type":43},"2022-05-12",{"date":42,"type":22},{"name":747,"class":218},"Pakistan Council of Scientific and Industrial Research",{"id":749,"slug":750,"hasResults":11,"nctId":751,"briefTitle":752,"officialTitle":752,"acronym":4,"eligibilityCriteria":753,"healthyVolunteers":16,"sex":17,"minAge":754,"maxAge":755,"enrollmentInfo":756,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":757,"conditions":758,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":759,"lastUpdatePostDateStruct":760,"startDateStruct":762,"completionDateStruct":764,"leadSponsor":765,"locationsCount":49},"100521833","diagnostic-possibilities-in-ophthalmological-diseases-using-swept-source-optical-coherence-tomography-100521833","NCT06074731","Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography","Inclusion Criteria:\n\n* Age between 5 and 110 years\n* Ability to follow instructions during imaging procedure\n* Written Informed consent\n\nExclusion Criteria:\n\n* Dementia\n* Inability to follow instructions during imaging procedure\n* Patients who do not give informed consent","5 Years","110 Years",{"count":106,"type":22},"In this pilot study we want to investigate morphological features acquired by the novel image modality and gain information regarding disease pathomechanism, development and future possible influence on disease management for patients affected by those diseases.",[29,27,124],"2023-10-03",{"date":761,"type":43},"2023-10-10",{"date":763,"type":43},"2017-06-01",{"date":417,"type":22},{"name":766,"class":218},"Johannes Kepler University of Linz"]